I have a couple of points, and thanks for that question.
I think it's important to note that it's a suite of measures. It's not one or the other. Part of those measures include, absolutely, having the capacity for witnessed dosing based on assessment or any indication that there may be diversion. It includes random and regular urine drug screening. As part of these projects, some of it is witnessed dosing. It's not all just hydromorphone tablets. There are some injectable programs. There are a variety of different medications.
We are also requiring that projects provide a range of backbone medications so you could reduce the amount of additional safer supply or prescribed alternatives that a health care professional may want to prescribe to a patient.
It's a range of measures that are being taken. There must be a capacity to witness, depending on the assessment, and to work with them. There are projects that absolutely have injectable and other observed dosing.
I will note that in Switzerland, with heroin-assisted treatment—and I'll pass it on to my associate deputy, who was just there—they have witnessed as well as carries. All of this is being undertaken with regular monitoring, reporting and evaluation, which will inform our work.